Published: November 18, 2021
SYDNEY, November 18 , 2021 /PRNewswire/ — Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Australian oncology-focused biotechnology company, is pleased to share positive interim data from its ongoing phase 3 study of paxalisib